Short CommunicationExpression of 11β-hydroxysteroid dehydrogenase isoforms in canine adrenal glands treated with Trilostane (cas 13647-35-3)

Add time:09/09/2019    Source:sciencedirect.com

Trilostane, a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, is often used to treat canine hyperadrenocorticism. In some species, trilostane has been shown to have additional effects on steroid biosynthesis, and it has been postulated that trilostane might have effects on 11β-hydroxysteroid dehydrogenase (11β-HSD) in dogs. To investigate the effect of trilostane on 11β-HSD in canine adrenal glands, healthy Beagle dogs were treated with trilostane for 8 weeks. Trilostane treatment resulted in a significant decrease of the cortisol/cortisone ratio in the serum. The adrenal gland mRNA and protein expression levels of 11β-HSD type 1 and 11β-HSD type 2 were significantly higher and significantly lower respectively in dogs treated with trilostane compared to those in control healthy Beagle dogs. These findings suggest that trilostane may have an effect on 11β-HSD activity in canine adrenal glands.

We also recommend Trading Suppliers and Manufacturers of Trilostane (cas 13647-35-3). Pls Click Website Link as below: cas 13647-35-3 suppliers

Prev:Possible Therapeutic Effect of Trilostane (cas 13647-35-3) in Rodent Models of Inflammation and Nociception
Next:Topical reviewMedical Management of Pituitary-Dependent Hyperadrenocorticism: Mitotane versus Trilostane (cas 13647-35-3))